HSBC has added another 7.5% this week alone, closing at £14.096, and the question the market is now asking is whether the re-rating has moved fast enough to outrun the fundamentals.
The valuation shift this week is the standout detail. The price-to-book multiple has expanded to 1.70x, up nearly 9% in seven days and the sharpest weekly move in the metric over the past month. The PE has climbed to 10.6x, gaining roughly 0.75 turns on the week. Both multiples are now materially above where they were a month ago. The earnings-momentum story that justified the original re-rating remains intact — HSBC ranks in the 92nd percentile for EPS surprise and the 82nd percentile for 30-day earnings momentum — but the stock has now priced in a good deal of that good news. The bulls' argument that the bank was cheap at 9.9x PE and 1.59x book, which last week's note made a feature of, carries less force at 10.6x and 1.70x.
The lending market is, if anything, even less of a short-seller story than it was last week. Availability is at the ORTEX system ceiling — there is effectively no meaningful borrowing demand anywhere in the pool. Cost to borrow eased further to 0.66%, its lowest level of the past month and down from the 0.89% peak in late May. The ORTEX short score has drifted modestly lower over the past ten days, to 26.3, a reading that places HSBC in the 85th percentile for its short score rank — meaning shorts are lighter here than at almost any comparable bank. There is no squeeze story, no borrow squeeze pressure, and no sign that short sellers are rebuilding. The borrow market describes a stock that institutions are simply not betting against.
The peer group moved with HSBC this week, but HSBC outran most of them. STAN rose 10.3% and SAN gained 11.0%, the two closest rivals in weekly return. BARC added 8.7%, while LLOY and NWG each gained around 6%. The sector bid was broad, which means HSBC's move is less a stock-specific re-rating than participation in a European banking rally. That context matters: when the sector pulls back, HSBC will have less idiosyncratic protection than a name moving on company-specific news.
The institutional picture adds one detail worth noting. BlackRock added roughly 80 million shares in its most recent filing, and JP Morgan Asset Management added a similar number — both reported within the past month. Those are meaningful additions for the two largest external holders, and they predate this week's price action. Ping An, the second-largest holder at 8.76% of shares, held flat. The insider picture is quieter: the most recent trades were mostly small sells in March and early May, consistent with vest-and-sell patterns rather than any directional conviction. Net insider activity over the past 90 days is modestly positive in share terms, though the value is driven largely by the March award-and-sell cycle.
The next hard fundamental test is the August 4 H1 results. Between now and then, the stock's trajectory depends on whether the European banking rally holds, whether the French probe overhang remains dormant, and — most acutely — whether the Allianz bid for the Singapore insurance arm produces a headline that refreshes the asset-disposal thesis at a price the market considers accretive. At 1.70x book and 10.6x earnings, HSBC no longer has the valuation cushion it carried into last week's trade.
See the live data behind this article on ORTEX.
Open HSBA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
